Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [ 177 Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Hong SongMaria Isabel LeonioValentina FerriHeying DuanCarina Mari ApariciGuido DavidzonBenjamin L FrancFarshad MoradiJagruti ShahColin P BergstromAlice C FanSumit ShahAli Raza KhakiSandy SrinivasAndrei H IagaruPublished in: European journal of nuclear medicine and molecular imaging (2024)
Lu]Lu-PSMA-617 infusions. Quantitation of 1-2 h post-therapy SPECT/CT images is a promising method for assessing treatment response. However, the approach is currently limited by its suboptimal detection of small tumor lesions and the necessity of incorporating a third-cycle SPECT/CT to mitigate the effects of any potential treatment-related flare-up. Further investigation in a larger patient cohort and prospective validation is essential to confirm these findings and to explore the role of SPECT/CT as a potential adjunct to PSMA PET/CT in managing mCRPC.
Keyphrases
- pet ct
- positron emission tomography
- image quality
- dual energy
- computed tomography
- contrast enhanced
- squamous cell carcinoma
- high resolution
- small cell lung cancer
- mass spectrometry
- stem cells
- deep learning
- magnetic resonance
- case report
- risk assessment
- bone marrow
- cell therapy
- photodynamic therapy
- liquid chromatography